Acquired by Sumitovant Biopharma in Mar 2023
MYOV - Myovant Sciences Ltd.
NYSE
->
Healthcare
->
Biotechnology
London,
United Kingdom
Type: Equity
MYOV price evolution
MYOV
| (in millions $) | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $341.96 | $325.54 | $406.7 | |
| Short term investments | $29.33 | $31.22 | $27.48 | |
| Net receivables | $44.02 | $34.7 | $30.11 | $23.88 |
| Inventory | $30.08 | $23.05 | $21.22 | $7.58 |
| Total current assets | $386.59 | $460.91 | $426.83 | $488.14 |
| Long term investments | $1.94 | |||
| Property, plant & equipment | $9.64 | $9.73 | $10.18 | $10.9 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $23.06 | $33.3 | $31.87 | |
| Total investments | $29.33 | $33.15 | $27.48 | |
| Total assets | $403.52 | $483.97 | $460.13 | $520.01 |
| Current liabilities | ||||
| Accounts payable | $12.22 | $9.07 | $9.93 | $12.64 |
| Deferred revenue | $496.55 | $451.13 | $476.27 | |
| Short long term debt | $2.37 | $2.26 | $2.15 | |
| Total current liabilities | $245.75 | $251.69 | $226.24 | $250.33 |
| Long term debt | $358.7 | $364.49 | $365.13 | $365.74 |
| Total noncurrent liabilities | $745.53 | $717.41 | $743.16 | |
| Total debt | $366.86 | $367.39 | $367.89 | |
| Total liabilities | $961.66 | $997.22 | $943.65 | $993.49 |
| Shareholders' equity | ||||
| Retained earnings | -$1376.61 | -$1318.99 | -$1273.37 | -$1252.13 |
| Other shareholder equity | -$17.29 | -$17.29 | -$17.29 | -$17.29 |
| Total shareholder equity | -$513.25 | -$483.52 | -$473.48 | |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $406.7 | $674.49 | $76.64 | $156.07 |
| Short term investments | $27.48 | $10.44 | $3 | |
| Net receivables | $23.88 | $3.57 | $3.57 | |
| Inventory | $7.58 | $2.61 | $2.61 | |
| Total current assets | $488.14 | $704.64 | $87.91 | $166.79 |
| Long term investments | ||||
| Property, plant & equipment | $10.9 | $12.96 | $13.64 | $2.07 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $31.87 | $20.38 | $18.02 | $6.18 |
| Total investments | $27.48 | $10.44 | $3 | |
| Total assets | $520.01 | $725.03 | $105.93 | $172.98 |
| Current liabilities | ||||
| Accounts payable | $12.64 | $18.35 | $15.35 | $13.41 |
| Deferred revenue | $476.27 | $497.93 | $40 | $40 |
| Short long term debt | $2.15 | $1.81 | $1.52 | $6.14 |
| Total current liabilities | $250.33 | $281.34 | $85.92 | $71.97 |
| Long term debt | $365.74 | $367.89 | $124.7 | $93.24 |
| Total noncurrent liabilities | $743.16 | $797.65 | $128.28 | $96.67 |
| Total debt | $367.89 | $369.7 | $126.21 | $99.38 |
| Total liabilities | $993.49 | $1078.99 | $214.2 | $168.64 |
| Shareholders' equity | ||||
| Retained earnings | -$1252.13 | -$1046.15 | -$791.01 | -$502.02 |
| Other shareholder equity | -$17.29 | -$17.29 | -$1.65 | $0.51 |
| Total shareholder equity | -$473.48 | -$353.96 | -$108.28 | $4.33 |
| (in millions $) | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $104.82 | $116.49 | $57.57 | |
| Cost of revenue | $27.36 | $22.93 | $17.74 | |
| Gross Profit | $77.46 | $93.56 | $39.83 | |
| Operating activities | ||||
| Research & development | $26.92 | $23.89 | $24.52 | |
| Selling, general & administrative | $84.26 | $79.03 | $67.25 | |
| Total operating expenses | $111.17 | $102.92 | $91.76 | |
| Operating income | -$33.71 | -$9.36 | -$51.94 | |
| Income from continuing operations | ||||
| EBIT | -$32.69 | -$8.88 | -$51.8 | |
| Income tax expense | $8.11 | $8.16 | $3.99 | |
| Interest expense | $4.81 | $4.2 | $3.49 | |
| Net income | ||||
| Net income | -$45.62 | -$21.24 | -$59.28 | |
| Income (for common shares) | -$45.62 | -$21.24 | -$59.28 | |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $230.97 | $59.32 | ||
| Cost of revenue | $51.55 | $1.97 | ||
| Gross Profit | $179.42 | $57.35 | ||
| Operating activities | ||||
| Research & development | $107.4 | $136.71 | $192.56 | $222.61 |
| Selling, general & administrative | $259.36 | $181.42 | $82.33 | $42.22 |
| Total operating expenses | $366.77 | $318.14 | $274.89 | $264.83 |
| Operating income | -$187.35 | -$260.78 | -$274.89 | -$264.83 |
| Income from continuing operations | ||||
| EBIT | -$186.96 | -$244.4 | -$275.56 | -$264.25 |
| Income tax expense | $5.05 | $0.34 | $0.76 | $0.48 |
| Interest expense | $13.97 | $10.4 | $12.66 | $8.82 |
| Net income | ||||
| Net income | -$205.98 | -$255.13 | -$288.99 | -$273.55 |
| Income (for common shares) | -$205.98 | -$255.13 | -$288.99 | -$273.55 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$45.62 | -$21.24 | -$59.28 | -$63.45 |
| Operating activities | ||||
| Depreciation | $0.81 | $0.8 | $0.76 | $0.78 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.72 | $9.71 | $8.6 | $7.2 |
| Total cash flows from operations | $9.12 | -$76 | -$100.09 | -$91.89 |
| Investing activities | ||||
| Capital expenditures | -$0.31 | -$0.07 | -$0.25 | -$0.36 |
| Investments | $3.82 | -$5.67 | $42.54 | $27.83 |
| Total cash flows from investing | $3.51 | -$5.74 | $42.29 | $27.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.95 | $1.19 | $6.76 | $4.01 |
| Net borrowings | ||||
| Total cash flows from financing | $3.95 | $1.19 | $6.76 | $4.01 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $16.58 | -$80.56 | -$51.04 | -$60.42 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$205.98 | -$255.13 | -$288.99 | -$273.55 |
| Operating activities | ||||
| Depreciation | $3.07 | $2.48 | $1.76 | $0.44 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $38.93 | $53.68 | $40.25 | $18.7 |
| Total cash flows from operations | -$268.56 | $370.63 | -$221.17 | -$224.09 |
| Investing activities | ||||
| Capital expenditures | -$0.97 | -$1.77 | -$1.1 | -$1.24 |
| Investments | -$17.05 | -$7.44 | -$2.84 | |
| Total cash flows from investing | -$18.02 | -$9.21 | -$3.94 | -$1.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $25.91 | $6.71 | $137.95 | $220.22 |
| Net borrowings | $245 | $8.28 | $53.97 | |
| Total cash flows from financing | $25.91 | $238.04 | $145.93 | $273.9 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$260.68 | $599.46 | -$79.18 | $48.58 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 97.03M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -2.10 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.57 |
| Quick ratio | 1.45 |